Erythropoietin receptor peptide formulations and uses

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/17 (2006.01)

Patent

CA 2609401

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

La présente invention concerne des composés peptidiques qui sont des agonistes du récepteur de l'érythropoïétine (EPO-R). L'invention concerne également des méthodes thérapeutiques faisant appel auxdits composés peptidiques pour traiter des troubles associés à une production de globules rouges insuffisante ou défectueuse. L'invention concerne en outre des compositions pharmaceutiques, lesquelles comprennent les composés peptidiques de l'invention, ainsi que des doses.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Erythropoietin receptor peptide formulations and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Erythropoietin receptor peptide formulations and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietin receptor peptide formulations and uses will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1858936

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.